Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009359 | 1.00 | MAOA (0.38) | MAOAMAOBPOLBSIGMAR1HTR1A | |
| SCHEMBL1009707 | 1.00 | MAOA (0.38) | MAOAMAOBPOLBSIGMAR1HTR1A | |
| SCHEMBL180960 | 0.98 | MAOA (0.39) | MAOAMAOBPOLBSIGMAR1HTR1A | |
| SCHEMBL706405 | 0.91 | MAOA (0.35) | MAOAMAOBPOLBSIGMAR1HTR1A | |
| SCHEMBL8019177 | 0.90 | MAOA (0.34) | MAOAMAOBPOLBSIGMAR1LMNA | |
| SCHEMBL11267300 | 0.88 | MAOA (0.35) | MAOAMAOBHTR1AKDM1AADRA1D | |
| SCHEMBL3886896 | 0.88 | MAOA (0.39) | MAOAMAOBHTR1AMEN1KMT2A | |
| SCHEMBL3885101 | 0.88 | MAOA (0.35) | MAOAMAOBPOLBHTR1ALMNA | |
| SCHEMBL8678876 | 0.87 | MEN1 (0.36) | MAOAMAOBPOLBSIGMAR1MEN1 | |
| SCHEMBL10974727 | 0.85 | TDP1 (0.33) | MAOAMAOBHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124930-A1 | PROCESS | MEXICHEM AMANCO HOLDING S.A. DE C.V. (MX) | 2011-05-26 | — | — | US | disclosed |
| US-20110118513-A1 | PROCESS | INEOS FLUOR HOLDINGS LIMITED (GB) | 2011-05-19 | — | — | US | disclosed |
| US-20110112340-A1 | PROCESS | MEXICHEM AMANCO HOLDING S.A. DE C.V. (MX) | 2011-05-12 | — | — | US | disclosed |
| US-20110112338-A1 | Process for the Preparation of 2,3,33-Trifluoropropene | MEXICHEM/ AMANCO HOLDING S.A. DE C.V. (MX) | 2011-05-12 | — | — | US | disclosed |
| EP-2297073-A1 | PROCESS FOR THE PREPARATION OF 2, 3, 3, 3-TRIFLUOROPROPENE | Mexichem Amanco Holdings S.A. de C.V. (MX) | 2011-03-23 | — | — | EP | disclosed |
| EP-2294040-A2 | PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOROPROPENE | Mexichem Amanco Holdings S.A. de C.V. (MX) | 2011-03-16 | — | — | EP | disclosed |
| EP-2285761-A2 | PROCESS FOR THE PREPARATION OF 1,1,1-TRIFLUORO-2,3-DICHLOROPROPANE | Mexichem Amanco Holdings S.A. de C.V. (MX) | 2011-02-23 | — | — | EP | disclosed |
| EP-2268595-A2 | PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOROPROPENE | Mexichem Amanco Holdings S.A. de C.V. (MX) | 2011-01-05 | — | — | EP | disclosed |
| EP-2121548-A2 | PROCESS FOR THE PREPARATION OF C3-7 FLUOROALKENES BY BASE-MEDIATED DEHYDROHALOGENATATION OF HYDROHALOGENATED C3-7 FLUOROALKANES | Ineos Fluor Holdings Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008075017-A2 | PROCESS FOR THE PREPARATION OF C3-7 FLUOROALKENES BY BASE-MEDIATED DEHYDROHALOGENATATION OF HYDROHALOGENATED C3 -7 FLUOROALKANES | INEOS FLUOR HOLDINGS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124930-A1 | PROCESS | CYP2F1, CYP4F3, CYP4F11 | MAOA 1882/4885MAOB 844/4885POLB 374/4885 |
| US-20110112340-A1 | PROCESS | CYP2F1, CYP4F11, CYP4F2 | MAOA 1349/4885MAOB 912/4885POLB 983/4885 |
| US-20110118513-A1 | PROCESS | DCAF1, CYP4F3, CLTB | MAOA 3903/4885MAOB 2436/4885POLB 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.